Floatz logo

Docetaxel

Thyroid Gland Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Thyroid Gland Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
ALECTINIB
Hoffmann-La Roche
Phase 2B
Denosumab
Amgen
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
[18f]f-resca-rt4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →